Article first published online: 22 MAR 2011
© 2011 John Wiley & Sons A/S
Volume 31, Issue 5, page 748, May 2011
How to Cite
(2011), ERRATA. Liver International, 31: 748. doi: 10.1111/j.1478-3231.2011.02531.x
- Issue published online: 3 APR 2011
- Article first published online: 22 MAR 2011
Vol. 31, Issue Supplement s1, 95–103, Article first published online: 4 JAN 2011
In the abstract of Papatheodoridis (1), the following statement is incorrect:
All NUCs are potent anti-hepatitis B virus agents (all except adefovir are more potent than IFN-α) with entecavir and tenofovir being the most potent. Most importantly NUCs all have minimal risk of resistance during long-term monotherapy.
The correct sentence should be:
All NUCs are potent anti-hepatitis B virus agents (all but adefovir are more potent than IFN-α) with entecavir (ETV) and tenofovir offering the highest potency and most importantly minimal to negligible risk of resistance during long-term monotherapy.